1. A class action lawsuit has been filed against LifeMD, Inc. 2. Investors allege securities fraud by LifeMD's officers and directors. 3. LifeMD's stock plunged 44.85% following revenue guidance revisions. 4. Investors can apply to be Lead Plaintiff until October 27, 2025. 5. Pomerantz LLP is leading the class action against LifeMD.
The lawsuit suggests significant governance issues, harming investor confidence. Historical examples show that similar lawsuits often lead to prolonged stock price declines.
The class action lawsuit is a critical risk factor for LFMD that could deter potential investors.
The immediate fallout from the lawsuit could constrain stock price recovery. Past cases reveal stocks often suffer in the wake of litigation.
NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. ("LifeMD" or the "Company")(NASDAQ:LFMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether LifeMD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until October 27, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired LifeMD securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On August 5, 2025, after the market closed, the Company issued a press release entitled "LifeMD Reports Second Quarter 2025 Results." This announcement quoted Chief Financial Officer Marc Benathen as stating that due to "some temporary challenges facing our Rex MD business," which he claimed were "largely resolved," that the Company was "revising our full year 2025 guidance for revenue and adjusted EBITDA to reflect the full-year impact of these issues, while still anticipating strong year-over-year growth in both metrics."
On this news, LifeMD's stock price fell $5.31 per share, or 44.85%, to close at $6.53 per share on August 6, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-lifemd-inc-of-class-action-lawsuit-and-upcoming-deadlines---lfmd-302549455.html
SOURCE Pomerantz LLP